<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immix Biopharma Inc — News on 6ix</title>
<link>https://6ix.com/company/immix-biopharma-inc</link>
<description>Latest news and press releases for Immix Biopharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immix-biopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835838078dffbe2df0fcb89.webp</url>
<title>Immix Biopharma Inc</title>
<link>https://6ix.com/company/immix-biopharma-inc</link>
</image>
<item>
<title>Immix Biopharma to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 12:45:00 GMT</pubDate>
<description>LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to re</description>
</item>
<item>
<title>Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsedrefractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsedrefractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned</description>
</item>
<item>
<title>Immix Biopharma to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 13:45:00 GMT</pubDate>
<description>LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences: Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL. The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL. Company</description>
</item>
<item>
<title>Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-receives-u-fda-134500068</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-receives-u-fda-134500068</guid>
<pubDate>Wed, 28 Jan 2026 13:45:00 GMT</pubDate>
<description>– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by planned BLA submission – LOS ANGELES, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that the U.S. Food and Drug Administration</description>
</item>
<item>
<title>Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-closing-upsized-224500861</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-closing-upsized-224500861</guid>
<pubDate>Tue, 09 Dec 2025 22:45:00 GMT</pubDate>
<description>– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-fun</description>
</item>
<item>
<title>Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-pricing-upsized-232000106</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-pricing-upsized-232000106</guid>
<pubDate>Sun, 07 Dec 2025 23:20:00 GMT</pubDate>
<description>LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant,</description>
</item>
<item>
<title>At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/ash-2025-oral-presentation-immix-231500985</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/ash-2025-oral-presentation-immix-231500985</guid>
<pubDate>Sun, 07 Dec 2025 23:15:00 GMT</pubDate>
<description>– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% – – NEXICART-2 final readout and BLA submission planned in 2026 – LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory</description>
</item>
<item>
<title>Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-appoints-chief-commercial-134500574</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-appoints-chief-commercial-134500574</guid>
<pubDate>Wed, 12 Nov 2025 13:45:00 GMT</pubDate>
<description>- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s U.S. launch and commercial buildout for NXC-201 in relapsed/refractory AL Amyloidosis, a serious, rare, blood disease with no currently approved FDA therapies - LOS ANGELES, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We”</description>
</item>
<item>
<title>Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-nxc-201-nexicart-134500867</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-nxc-201-nexicart-134500867</guid>
<pubDate>Mon, 03 Nov 2025 13:45:00 GMT</pubDate>
<description>- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florid</description>
</item>
<item>
<title>Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-guggenheim-2nd-124500735</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-guggenheim-2nd-124500735</guid>
<pubDate>Tue, 14 Oct 2025 12:45:00 GMT</pubDate>
<description>LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA. Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time. The Company will be available fo</description>
</item>
<item>
<title>Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-abstract-upcoming-200500902</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-abstract-upcoming-200500902</guid>
<pubDate>Mon, 06 Oct 2025 20:05:00 GMT</pubDate>
<description>Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid pro</description>
</item>
<item>
<title>Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-37th-annual-124500123</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-37th-annual-124500123</guid>
<pubDate>Wed, 01 Oct 2025 12:45:00 GMT</pubDate>
<description>Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one</description>
</item>
<item>
<title>Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-50-enrollment-173000401</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-50-enrollment-173000401</guid>
<pubDate>Thu, 18 Sep 2025 17:30:00 GMT</pubDate>
<description>– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 50% enrollment milestone has already been surpassed in NEXICART-2, its relapsed/refractory AL Amylo</description>
</item>
<item>
<title>Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/nancy-t-chang-proven-biotechnology-131500566</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/nancy-t-chang-proven-biotechnology-131500566</guid>
<pubDate>Thu, 11 Sep 2025 13:15:00 GMT</pubDate>
<description>– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with he</description>
</item>
<item>
<title>Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-strategic-investment-200500034</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-strategic-investment-200500034</guid>
<pubDate>Mon, 08 Sep 2025 20:05:00 GMT</pubDate>
<description>LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGAR</description>
</item>
<item>
<title>Immix Biopharma to Present at the Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-stifel-2025-133000943</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-present-stifel-2025-133000943</guid>
<pubDate>Mon, 25 Aug 2025 13:30:00 GMT</pubDate>
<description>Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one meetings du</description>
</item>
<item>
<title>Immix Biopharma Announces Other Serious Diseases Strategy</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-other-serious-163000157</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-other-serious-163000157</guid>
<pubDate>Wed, 06 Aug 2025 16:30:00 GMT</pubDate>
<description>– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serio</description>
</item>
<item>
<title>Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-class-leading-133600365</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-class-leading-133600365</guid>
<pubDate>Fri, 11 Jul 2025 13:36:00 GMT</pubDate>
<description>– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today a</description>
</item>
<item>
<title>Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-accelerated-nexicart-133500389</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-announces-accelerated-nexicart-133500389</guid>
<pubDate>Mon, 07 Jul 2025 13:35:00 GMT</pubDate>
<description>– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced accelerated U.S</description>
</item>
<item>
<title>Immix Biopharma Attends FDA CEO Forum in Washington DC</title>
<link>https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-attends-fda-ceo-133900442</link>
<guid isPermaLink="true">https://6ix.com/company/immix-biopharma-inc/news/immix-biopharma-attends-fda-ceo-133900442</guid>
<pubDate>Fri, 06 Jun 2025 13:39:00 GMT</pubDate>
<description>– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters</description>
</item>
</channel>
</rss>